KR880001762B1 - Processes for preparing 2-substituted hydroxyimino-2-(5-amino-1,2,4-thiadiazol-3-yl)acetic or tis salt - Google Patents
Processes for preparing 2-substituted hydroxyimino-2-(5-amino-1,2,4-thiadiazol-3-yl)acetic or tis salt Download PDFInfo
- Publication number
- KR880001762B1 KR880001762B1 KR8200972A KR820000972A KR880001762B1 KR 880001762 B1 KR880001762 B1 KR 880001762B1 KR 8200972 A KR8200972 A KR 8200972A KR 820000972 A KR820000972 A KR 820000972A KR 880001762 B1 KR880001762 B1 KR 880001762B1
- Authority
- KR
- South Korea
- Prior art keywords
- amino
- thiadiazol
- compound
- salt
- salts
- Prior art date
Links
- 0 CC(*)=NC(C(C(O)=O)=NC)=NC Chemical compound CC(*)=NC(C(C(O)=O)=NC)=NC 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Description
본 발명은 2-치환된 하이드록시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일)초산 또는 그염의 새로운 제조방법 및 그 중간체에 관한 것이다.The present invention relates to a novel process for the preparation of 2-substituted hydroxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid or salts thereof and to intermediates thereof.
특히, 본 발명은 2-치환된 하이드록시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일)초산 또는 그염의 제조방법, 및 상기 제조방법에 유용한 중간체 및 이러한 중간체의 제조방법에 관한 것이다.In particular, the present invention provides a process for preparing 2-substituted hydroxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid or salts thereof, and intermediates useful for the preparation method and It relates to a method for producing an intermediate.
따라서, 본 발명의 목적은 우수한 항균력을 지닌 7-아실아미노 세파로스포린을 제조하는데 아실화제로서 유용한 2-치환된 하이드록시 이미노-2-(5-아미노-1,2,4-티아디아졸-3-일)초산 또는 그염의 새로운 제조방법을 제공하기 위한 것이다.Accordingly, an object of the present invention is a 2-substituted hydroxy imino-2- (5-amino-1,2,4-thiadiazole which is useful as an acylating agent to prepare 7-acylamino sephalosporin with good antibacterial activity. -3-yl) acetic acid or its salts to provide a new method of preparation.
본 발명의 다른 목적은 2-치환된 하이드록시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일)아세트산 또는 이것의 염의 제조방법에 유용한 새로운 중간체를 제공하는데 있다.It is another object of the present invention to provide novel intermediates useful for the preparation of 2-substituted hydroxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid or salts thereof. .
본 발명의 또 다른 목적은 상기 새로운 중간체의 제조방법을 제공하는데 있다. 2-치환된 하이드록시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일)초산은 다음과 같은 구조식으로 표시할 수 있다.Another object of the present invention is to provide a method for preparing the new intermediate. 2-substituted hydroxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid can be represented by the following structural formula.
상기구조식에서, R1은 적당한 치환체로 치환 가능한 저급알킬이거나, 저급알케닐, 저급알키닐 시클로알킬, 시클로(저급)알케닐, 적당한 치환체로 치환 가능한 아릴, 또는 옥소기로 치환된 S 함유 5원 헤테로시클릭기이다.Wherein R 1 is lower alkyl substitutable with a suitable substituent or lower alkenyl, lower alkynyl cycloalkyl, cyclo (lower) alkenyl, aryl substitutable with a suitable substituent, or S-containing 5-membered hetero substituted with oxo group It is a cyclic group.
본 발명에 따르면, 2-치환된-하이드록시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일)초산(Ⅰ) 또는 이것의 염은 다음 방법에 의해 제조할 수 있다.According to the present invention, 2-substituted-hydroxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (I) or a salt thereof can be prepared by the following method. Can be.
방법Way
여기서 R1은 상기 정의와 같으며, M은 알칼리 금속이다. 목적 화합물(Ⅰ)과 중간체(Ⅲ),(Ⅳ),(Ⅵ), 및 (Ⅷ)에서,Where R 1 is as defined above and M is an alkali metal. In target compound (I) and intermediates (III), (IV), (VI), and (iii),
로 표시되는 부분 구조식은 하기 구조식으로 표시되는 기하구조를 포함한다.Partial structural formulas represented by include the geometry represented by the following structural formula.
(식중, R1은 상기 정의와 같다.)(Wherein R 1 is as defined above)
본 명세서에서는, 상기 부분 구조식을 가진 모든 화합물에 대해서, 구조식(A)의 기하구조를 가진 화합물을 신(syn)이성체라 하고, 구조식(A´)의 기하구조를 가진 화합물은 안티(anti)이성체라 한다.In the present specification, for all compounds having the partial structural formula, the compound having the geometric structure of formula (A) is called a syn isomer, and the compound having the geometric structure of the structural formula (A ′) is an anti isomer. It is called.
목적 화합물(Ⅰ)의 적합한 염에는 염기 또는 산부가염을 포함하는 염이 있는데, 예를들면 무기염기를 가진 염, 즉 알칼리 금속염(예를 들면, 나트륨염, 칼륨염, 등), 알카리토류 금속염(예를들면, 칼슘염, 마그네슘염, 등)암모늄염, 유기염기를 가진 염, 즉 유기아민염(예를 들면, 트리에틸아민염, 피리딘염, 피콜린염, 에탄올아민염, 트리에탄올 아민염, 디시클로헥실아민염, N,N´-디벤질에틸렌디아민염, 등) ; 무기산부가염(예를들면, 염산염, 브롬산염, 황산염, 인산염, 등) ; 유기산부 가염, 즉 유기 카르복실산 부가염 또는 설폰산부가염, (예를들면, 포르메이트, 트리플루오로아세테이트, 메탄설포네이트, 벤젠설포네이트, 아세테이트, P-톨루엔설포네이트, 등) ; 염기 아미노산(예를 들면, 아르기닌등)을 가진 염등이 있다.Suitable salts of the desired compound (I) include salts containing base or acid addition salts, for example salts with inorganic bases, ie alkali metal salts (e.g. sodium salts, potassium salts, etc.), alkaline earth metal salts ( For example, calcium salts, magnesium salts, etc.) ammonium salts, salts with organic bases, i.e. organic amine salts (e.g. triethylamine salts, pyridine salts, picoline salts, ethanolamine salts, triethanol amine salts, dishes) Clohexylamine salt, N, N'-dibenzylethylenediamine salt, etc.); Inorganic acid addition salts (for example, hydrochloride, bromate, sulfate, phosphate, and the like); Organic acid addition salts, ie, organic carboxylic acid addition salts or sulfonic acid addition salts (eg, formate, trifluoroacetate, methanesulfonate, benzenesulfonate, acetate, P-toluenesulfonate, etc.); Salts having a basic amino acid (eg arginine).
본 명세서의 상세한 설명중, 적합한 실시예 및 각종 정의에 대한 설명은 본 발명의 범위내에 드는 것이며, 하기에 상세히 설명한다.In the detailed description of this specification, descriptions of suitable embodiments and various definitions are within the scope of the present invention, which will be described in detail below.
특별한 언급이 없는한, '저급'이란 용어는 1-6개의 탄소원자를 가지는 기를 의미한다.Unless stated otherwise, the term "lower" means a group having 1-6 carbon atoms.
적합한 저급알킬에는 1-6개의 탄소원자를 가진 직쇄 또는 측쇄 알킬이 있으며, 예를 들면, 메틸, 에틸, 프로필, 이소프로필, 부틸, 이소부틸, t-부틸, t-펜틸, 헥실등이 있다.Suitable lower alkyls are straight or branched chain alkyls having 1-6 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, t-pentyl, hexyl and the like.
적합한 치환체로 치환 가능한 '저급알킬'에 있어서, 적합한 치환체는 할로겐(예를 들면, 염소, 브롬, 불소, 또는 요오드), 카르복시 ; 저급알킬티오(예를 들면, 메틸티오, 에틸티오, 프로필티오, 부틸티오, 등) ; 아릴(예를 들면, 페닐, 톨릴, 크실릴, 메시틸, 큐메닐, 등);아릴옥시(예를 들면, 펜옥시, 톨릴옥시, 메시틸옥시, 등) ; 저급알콕시(저급)알콕시(예를 들면, 메톡시메톡시, 메톡시에톡시, 에톡시에톡시, 프로폭시에톡시, 부톡시에톡시, 펜틸옥시메톡시, 헥실옥시메톡시, 헥실옥시에톡시, 등) ; 하이드록시 ; 저급알칸 설포닐(예를 들면, 메실, 에탄설포닐, 프로판설포닐, 이소프로판설포닐, 부탄설포닐, 등) ; 할로겐으로 치환된 아릴(예를 들면 , 클로로페닐, 플루오로페닐, 등) ; 시아노 ; 하기에 설명하는 바와 같은 보호된 카르복시기등이다.For 'lower alkyl' substitutable with suitable substituents, suitable substituents include halogen (eg chlorine, bromine, fluorine, or iodine), carboxy; Lower alkylthio (eg, methylthio, ethylthio, propylthio, butylthio, etc.); Aryl (eg, phenyl, tolyl, xylyl, mesityl, cumenyl, etc.); aryloxy (eg, phenoxy, tolyloxy, mesityloxy, etc.); Lower alkoxy (lower) alkoxy (e.g., methoxymethoxy, methoxyethoxy, ethoxyethoxy, propoxyethoxy, butoxyethoxy, pentyloxymethoxy, hexyloxymethoxy, hexyloxyethoxy , Etc) ; Hydroxy; Lower alkanesulfonyl (eg, mesyl, ethanesulfonyl, propanesulfonyl, isopropanesulfonyl, butanesulfonyl, etc.); Aryl substituted with halogen (eg, chlorophenyl, fluorophenyl, etc.); Cyano; Protected carboxyl groups as described below.
적합한 "보호된 카르복시"에는 에스테르화 카르복시가 있으며, 에스테르화 카르복시중의 적합한 에스테르기의 예로는 저급알킬 에스테르(예를들면, 메틸에스테르, 에틸에스테르, 프로필에스테르, 이소프로필 에스테르, 부틸에스테르, 이소부틸에스테르, t-부틸에스테르, 펜틸에스테르, 헥실에스테르, 1-시클로프로필에스테르, 등)이 있으며, 이것은 저급 알카노일옥시(저급)알킬 에스테르(예를 들면, 아세톡시메틸 에스테르,프로피오닐옥시메틸 에스테르, 부티릴옥시메틸 에스테르, 발레릴옥시메틸 에스테르,피발로일옥시메틸 에스테르,2-아세톡시에틸 에스테르, 2-프로피오닐 옥시에틸-에스테르, 헥사노일옥시메틸 에스테르, 등), 저급알칸 설포닐(저급)알킬 에스테르(예를 들면, 2-메틸에틸에스테르, 등) 또는 모노(또는 디 또는 트리)할로(저급)알킬 에스테르(예를 들면, 2-요오도에틸, 2,2,2-트리클로로에틸 에스테르, 등)등의 적어도 하나의 적합한 치환체를 가질수도 있고 ; 저급 알케닐 에스테르(예를 들면, 비닐에스테르, 알릴 에스테르, 등) ; 저급 알키닐 에스테르(예를 들면, 에티닐 에스테르, 프로피닐 에스테르, 등) ; 적어도 하나의 적합한 치환체를 갖는 아르(저급)알킬 에스테르(예를 들면, 벤질 에스테르, 4-메톡시벤질 에스테르, 4-니트로벤질 에스테르, 펜에틸 에스테르,트리틸 에스테르, 벤즈히드릴에스테르, 비스(메톡시페닐)-메틸에스테르, 3,4-디메톡시 벤질 에스테르, 4-하이드록시-3,5-디-t-부틸벤질 에스테르, 등) ; 적어도 하나의 적합한 치환체를 갖는 아릴 에스테르(예를들면, 페닐에스테르, 4-클로로페닐 에스테르, 톨릴에스테르, t-부틸페닐 에스테르,크실릴 에스테르, 메시틸 에스테르, 큐메닐 에스테르, 등)등이 있다.Suitable “protected carboxys” include esterified carboxys, and examples of suitable ester groups in the esterified carboxy include lower alkyl esters (eg, methyl esters, ethyl esters, propyl esters, isopropyl esters, butyl esters, isobutyl) Esters, t-butyl esters, pentyl esters, hexyl esters, 1-cyclopropyl esters, etc.), which are lower alkanoyloxy (lower) alkyl esters (e.g. acetoxymethyl ester, propionyloxymethyl ester, Butyryloxymethyl ester, valeryloxymethyl ester, pivaloyloxymethyl ester, 2-acetoxyethyl ester, 2-propionyl oxyethyl-ester, hexanoyloxymethyl ester, etc., lower alkanesulfonyl (lower) Alkyl esters (eg, 2-methylethyl ester, etc.) or mono (or di or tri) halo (lower) alkyl groups; Termini Figure gajilsu at least one suitable substituent, such as (for example, 2-iodo-ethyl, 2,2,2-trichloroethyl ester, etc.), and; Lower alkenyl esters (eg, vinyl esters, allyl esters, etc.); Lower alkynyl esters (eg, ethynyl esters, propynyl esters, etc.); Ar (lower) alkyl esters having at least one suitable substituent (eg, benzyl ester, 4-methoxybenzyl ester, 4-nitrobenzyl ester, phenethyl ester, trityl ester, benzhydryl ester, bis (meth) Oxyphenyl) -methyl ester, 3,4-dimethoxy benzyl ester, 4-hydroxy-3,5-di-t-butylbenzyl ester, etc.); Aryl esters having at least one suitable substituent (eg, phenyl esters, 4-chlorophenyl esters, tolyl esters, t-butylphenyl esters, xylyl esters, mesityl esters, cumenyl esters, and the like).
적합한 저급 알케닐에는 비닐, 알릴, 이소 프로페닐, 1-프로페닐, 2-부테닐, 3-펜테닐 등이있으며, 2 내지 4의 탄소원자를 가진 것이 바람직하다.Suitable lower alkenyls include vinyl, allyl, isopropenyl, 1-propenyl, 2-butenyl, 3-pentenyl, and the like, with those having 2 to 4 carbon atoms being preferred.
적합한 저급 알기닐에는 2 내지 4의 탄소원자를 가진 것, 예를 들면 에티닐, 2-프로피닐, 2-부티닐, 3-펜티닐, 3-헥시닐 등이 있으며, 2 내지 4의 탄소원자를 가진 것이 바람직하다.Suitable lower alginyls include those having 2 to 4 carbon atoms, for example ethynyl, 2-propynyl, 2-butynyl, 3-pentynyl, 3-hexynyl, and the like, and those having 2 to 4 carbon atoms It is preferable.
적합한 시클로 알킬에는 3 내지 8의 탄소원자를 가진 것, 예를 들면 시클로프필, 시클로부틸, 시클로펜틸, 시클로헥실, 시클로 헵틸등이 있으며, 4 내지 7의 탄소원자를 가진 것이 바람직하다.Suitable cycloalkyls include those having from 3 to 8 carbon atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like, preferably having from 4 to 7 carbon atoms.
적합한 시클로(저급)알케닐에는 3 내지 6의 탄소원자를 가진 것, 예를 들면 시클로펜테닐, 시클로헥세닐등이 있으며, 5 내지 6의 탄소원자를 가진 것이 바람직하다.Suitable cyclo (lower) alkenyls include those having 3 to 6 carbon atoms, such as cyclopentenyl, cyclohexenyl, and the like, and those having 5 to 6 carbon atoms are preferred.
적합한 아릴에는 페닐, 톨릴, 크실릴, 메시틸, 큐메닐등이 있으며, 상기 아릴기는 다음과 같은 치환체 1개-3개로 치환 가능하다. : 할로겐(예를 들면, 염소, 브롬, 불소 또는 요오드), 니트로, 저급 알콕시(예를 들면, 메톡시, 에톡시, 프로폭시, 부톡시, 펜틸옥시, 헥실옥시, 등)로서 바람직하게는 1 내지 4의 탄소원자를 가진 것, 할로(저급) 알킬(예를 들면, 클로로메틸, 티클로로메틸, 트리클로로메틸, 트리플루오로메틸, 트리클로로에틸, 등)로서 바람직하게는 1 내지 3의 탄소원자를 가진 것, 카르복시등이다.Suitable aryls include phenyl, tolyl, xylyl, mesityl, cumenyl, and the like, wherein the aryl group can be substituted with one to three substituents as follows. Preferably as halogen (e.g. chlorine, bromine, fluorine or iodine), nitro, lower alkoxy (e.g. methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, etc.) Having from 1 to 4 carbon atoms, halo (lower) alkyl (e.g., chloromethyl, thichloromethyl, trichloromethyl, trifluoromethyl, trichloroethyl, etc.), preferably from 1 to 3 carbon atoms It has a ruler, carboxyl.
적합한 S 함유 5원 헤테로시클릭기에는 티올아닐등이 있으며, 이것은 1 또는 2의 옥소기로 치환된 것이다.Suitable S containing 5-membered heterocyclic groups include thiol anyl and the like, which are substituted with 1 or 2 oxo groups.
다음은 목적 화합물(Ⅰ) 또는 그의 염의 제조방법을 상세히 설명한다.The following describes in detail the preparation of the target compound (I) or salt thereof.
방법 1Method 1
화합물 (Ⅲ) 또는 그것의 염의 화합물(Ⅱ)를 니트로소화 시킴으로써 제조 할 수 있다.It can manufacture by nitrosing compound (II) of compound (III) or its salt.
화합물(Ⅲ)의 적합한 염에는 알칼리 금속염(예를 들면, 나트륨염, 칼륨염)등이 있다.Suitable salts of compound (III) include alkali metal salts (eg sodium salts, potassium salts).
반응중 사용되는 니트로소화제는 종래의 것인데, 이것은 활성메틸렌 화합물과 반응해서 C-니트로소화합물, 즉 아질산 또는 아질산화 알칼리 금속(예를 들면, 아질산화나트륨, 등)과 같은 그들의 염 또는 저급 알킬 아질산염(예를들면, t-부틸 아질산염, 이소펜틸아질산염,등)등과 같은 그들의 에스테르를 생성한다. 아질산염이 니트로소화제로 사용될 경우, 반응은 염산, 황산, 초산등의 무기산 또는 유기산 존재하에서 행해진다. 이에 비해, 아질산에스테르가 니트로소화제로 사용될 경우, 반응은 알칼리 금속 알콕사이드(예를 들면, 나트륨 메톡사이드, 나트륨 에톡사이드, 칼륨 t-부톡사이드, 등)등과 같은 다소 강염기의 존재하에서 행하는 것이 바람직하다.Nitrogenating agents used during the reaction are conventional, which react with the active methylene compound to form C-nitroso compounds, ie their salts such as nitrous acid or nitrite alkali metals (eg sodium nitrite, etc.) or lower alkyl nitrites. To produce their esters (e.g., t-butyl nitrite, isopentyl nitrite, etc.). When nitrite is used as the nitrosizing agent, the reaction is carried out in the presence of inorganic or organic acids such as hydrochloric acid, sulfuric acid, acetic acid and the like. In contrast, when nitrite ester is used as the nitrosigating agent, the reaction is preferably carried out in the presence of a rather strong base such as alkali metal alkoxides (eg sodium methoxide, sodium ethoxide, potassium t-butoxide, etc.).
본 반응은 일반적으로 물, 초산, 알코올(예를 들면, 에탄올, 메탄올, 등), 에테르, 테트라하이드로퓨란과 같은 용매 또는 반응에 역영향을 끼치지 않는 다른 용매중에서 행해진다.The reaction is generally carried out in solvents such as water, acetic acid, alcohols (eg ethanol, methanol, etc.), ethers, tetrahydrofuran or other solvents that do not adversely affect the reaction.
반응온도가 한정되는 것은 아니나, 반응은 일반적으로 냉각 또는 가열하에서 행한다.Although the reaction temperature is not limited, the reaction is generally carried out under cooling or heating.
방법 2Method 2
화합물(Ⅳ)와 그것의 염은 화합물(Ⅲ) 또는 그것의 염의 하이드록시이미노기에 치환체가 첨가 반응을 행하여 제조할 수 있다.Compound (IV) and salts thereof can be prepared by addition of a substituent to the hydroxyimino group of compound (III) or salts thereof.
화합물 (Ⅳ)의 적합한 염은 화합물(Ⅰ)에서 예를 든 염기의 염과 같다.Suitable salts of compound (IV) are the same as the salts of the bases given in compound (I).
하이드록시이미노기에 치환체를 첨가하는 반응에 사용되는 시약에는 하기 구조식(Ⅸ) 또는 (Ⅹ)의 화합물이 있다.The reagent used for the reaction which adds a substituent to a hydroxyimino group contains the compound of the following structural formula (i) or (i).
R1― Y (Ⅸ)R 1 ― Y (Ⅸ)
식중, R1은 상기 정의와 같고, Y는 산잔기이다.Wherein R 1 is as defined above and Y is an acid residue.
R1a=N2(Ⅹ)R 1a = N 2
식중, R1a은 R1에서 수소 하나가 제거된 기이다.Wherein R 1a is a group in which one hydrogen is removed from R 1 .
첨가된 치환체가 적합한 치환체로 치환 가능한 아릴인 경우, 상기 시약과 더불어 하기 구조식(ⅩⅠ)의 화합물도 히드록시 아미노기에 치환체를 첨가하는 반응에 사용할 수 있다.When the added substituent is an aryl which can be substituted with a suitable substituent, the compound of the following structural formula (XI) can be used in the reaction of adding a substituent to the hydroxy amino group in addition to the above reagent.
R1b-X-R1bY(ⅩⅠ)R 1b -X -R 1b Y (ⅩⅠ)
식중, Y는 상기 정의한 바와 같고, R1b는 적합한 치환체로 치환 가능한 아릴이며, X는 할로겐이다.Wherein Y is as defined above, R 1b is aryl which may be substituted with a suitable substituent and X is halogen.
적당한 산잔기에는 할로겐화수소산(예를 들면, 염산, 브로화수소산, 요오드화 수소산, 등), 황산, 알킬 황산(예를 들면, 메틸황산, 에틸황산등), 설폰산 (예를 들면, 메탄설폰산, P-톨루엔 설폰산, 등)이다.Suitable acid residues include hydrofluoric acid (eg hydrochloric acid, hydrobromic acid, hydroiodic acid, etc.), sulfuric acid, alkyl sulfuric acid (eg methyl sulfuric acid, ethyl sulfuric acid, etc.), sulfonic acid (eg methanesulfonic acid). , P-toluene sulfonic acid, etc.).
화합물(Ⅸ)을 사용하는 반응은 일반적으로 물, 아세토니트릴, 아세톤, 에탄올, 에틸 아세테이트, 디메틸포름아미드 또는 반응에 역영향을 미치지 않는 용매중에서 행하며, 염기, 예를 들면 알칼리 금속 수산화물(예를 들면, 수산화나트륨, 수산화칼륨, 등), 알칼리 금속 중탄산염(예를 들면, 중탄산나트륨, 중탄산 칼륨, 등) 또는 알칼리 금속 탄산염(예를 들면, 탄산 나트륨, 탄산칼륨, 등)과 같은 무기염기, 또는 알칼리 금속 알콕사이드(예를 들면, 나트륨 메톡사이드, 나트륨 에톡사이드, 등), 트리알킬아민(예를 들면, 트리메틸아민, 트리에틸아민, 등), 트리에탄올 아민, N,N-디메틸아닐린, N,N-디메틸벤질아민, N-메틸모르폴린 또는 피리딘과 같은 유기염기 중에서 행하는 것이 바람직하다.The reaction using the compound (iii) is generally carried out in water, acetonitrile, acetone, ethanol, ethyl acetate, dimethylformamide or a solvent which does not adversely affect the reaction, and may be a base such as an alkali metal hydroxide (e.g. Inorganic bases such as sodium hydroxide, potassium hydroxide, etc.), alkali metal bicarbonates (eg sodium bicarbonate, potassium bicarbonate, etc.) or alkali metal carbonates (eg sodium carbonate, potassium carbonate, etc.), or alkalis Metal alkoxides (eg sodium methoxide, sodium ethoxide, etc.), trialkylamines (eg trimethylamine, triethylamine, etc.), triethanol amines, N, N-dimethylaniline, N, N- It is preferable to carry out in an organic base such as dimethylbenzylamine, N-methylmorpholine or pyridine.
반응온도는 한정되지 않으며 반응은 냉각 또는 가열하에서 행해진다.The reaction temperature is not limited and the reaction is carried out under cooling or heating.
화합물(Ⅹ)의 대표적인 예는 디아조(저급)알칼(예를 들면, 디아조메탄, 디아조에탄)이다. 화합물(Ⅹ)을 사용하는 반응은 일반적으로 에테르, 테트라하이드로퓨란같은 용매중에서 행해진다.Representative examples of the compound (VII) are diazo (lower) alkales (for example, diazomethane, diazoethane). The reaction using the compound (VII) is generally carried out in a solvent such as ether or tetrahydrofuran.
반응온도는 한정되지 않으며 반응은 냉각하에서 또는 실온에서 행해진다.The reaction temperature is not limited and the reaction is carried out under cooling or at room temperature.
화합물(ⅩⅠ)을 사용한는 반응은 일반적으로 알코올(예를 들면, 메탄올, 에탄올, 등)물, 그들의 혼합용매 또는 반응에 역영향을 주지 않는 용매중에서 행해지며, 염기 존재하에서 행하는 것이 바람직하다.The reaction using the compound (XI) is generally carried out in alcohol (for example, methanol, ethanol, etc.) water, their mixed solvent or a solvent which does not adversely affect the reaction, and is preferably carried out in the presence of a base.
반응온도는 한정되지 않으며 반응은 냉각 내지 가열하에서 행해진다.The reaction temperature is not limited and the reaction is carried out under cooling to heating.
방법 3Method 3
화합물(Ⅴ)과 이것의 염은 화합물(Ⅳ)와 이것의 염을 탈수시킴으로써 제조할 수 있다.Compound (V) and salts thereof can be prepared by dehydrating Compound (IV) and salts thereof.
화합물(Ⅴ)의 적합한 염은 화합물(Ⅰ)에서 예시한 염기의 염과 동일하다.Suitable salts of compound (V) are the same as the salts of the bases exemplified in compound (I).
본 탈수반응에서 사용되는 탈수제는 염화포스포릴, 염화티오닐, 오산화인, 오염화인, 오브롬화인 등이다. 본 반응은 일반적으로 디옥산, 클로로포름, 메틸렌 클로라이드, 1,2-디클로로에탄, 테트라하이드로 퓨란, 피리딘, 아세토니트릴, 디메틸포름아미드와 같은 용매 또는 반응에 역영향을 미치지 않는 다른 용매중에서 행해진다.The dehydrating agent used in this dehydration reaction is phosphoryl chloride, thionyl chloride, phosphorus pentoxide, phosphorus pentachloride, phosphorus oromide and the like. The reaction is generally carried out in solvents such as dioxane, chloroform, methylene chloride, 1,2-dichloroethane, tetrahydrofuran, pyridine, acetonitrile, dimethylformamide or other solvents that do not adversely affect the reaction.
반응 온도는 한정되지 않으며 반응은 일반적으로 실온, 또는 가열하에서 행해진다.The reaction temperature is not limited and the reaction is generally carried out at room temperature or under heating.
방법 4Method 4
화합물(Ⅵ) 혹은 이것의 화합물(Ⅴ) 또는 이것의 염을 암모니아 및/또는 암모늄염과 반응시켜서 제조할 수 있다.Compound (VI) or compound (V) or salt thereof can be prepared by reacting with ammonia and / or ammonium salt.
적합한 암모늄염에는 암모늄 아세테이트, 암모늄 설페이트, 암모늄-할라이드(예를 들면, 암모늄 클로라이드, 암모늄 브로마이드 등)등이 있다. 화합물(Ⅵ)의 적합한 염은 화합물(Ⅰ)에서 예시한 것과 같다.Suitable ammonium salts include ammonium acetate, ammonium sulfate, ammonium-halides (eg ammonium chloride, ammonium bromide, etc.). Suitable salts of compound (VI) are as exemplified for compound (I).
본 반응은 일반적으로, 물, 알코올(예를 들면, 메탄올, 에탄올, 등)아세톤, 클로로포름, 디메틸포름아미드, 디메틸설폭사이드, 아세토니트릴, 테트라하이드로퓨란, 또는 반응에 역영향을 미치지 않는 용매중에서 수행된다. 반응 온도는 한정되지 않으며 반응은 일반적으로 냉각하에서 또는 실온에서 행한다.The reaction is generally carried out in water, alcohol (eg methanol, ethanol, etc.) acetone, chloroform, dimethylformamide, dimethylsulfoxide, acetonitrile, tetrahydrofuran, or a solvent that does not adversely affect the reaction. do. The reaction temperature is not limited and the reaction is generally carried out under cooling or at room temperature.
방법 5Method 5
화합물(Ⅷ) 또는 그것의 화합물(Ⅵ) 또는 그것의 염을 할로겐화제 및 화합물(Ⅶ)과 반응시켜서 제조할 수 있다.Compound (VII) or compound (VI) or salt thereof can be prepared by reacting with a halogenating agent and compound (VII).
본 반응에서 사용하기에 적합한 할로겐화제는 브롬, 염소, 등이다. 화합물(Ⅷ)의 적합한 염은 화합물(Ⅰ)에서 예시한 것과 같다.Suitable halogenating agents for use in this reaction are bromine, chlorine, and the like. Suitable salts of compound (iii) are the same as those exemplified for compound (I).
M에 해당하는 적합한 알칼리 금속은 나트륨, 칼륨등이다.Suitable alkali metals corresponding to M are sodium, potassium and the like.
본 반응은 무기염기 또는 유기염기, 예를 들면, 알칼리 금속 탄산염, 알칼리 금속 알콕사이드, 트리알킬아민 등과 같은 염기의 존재하에서, 행하는 것이 바람직하다.The present reaction is preferably carried out in the presence of a base such as an inorganic base or an organic base such as an alkali metal carbonate, an alkali metal alkoxide, trialkylamine or the like.
본 반응은 일반적으로 알코올(예를 들면, 메탄올, 에탄올, 등) 또는 반응에 역영향을 미치지 않는 다른 용매중에서 행한다.The reaction is generally carried out in alcohol (eg methanol, ethanol, etc.) or other solvent that does not adversely affect the reaction.
반응 온도는 한정되지 않으며 반응 일반적으로 냉각하에서 또는 실온에서 행한다.The reaction temperature is not limited and the reaction is generally carried out under cooling or at room temperature.
방법 6Method 6
화합물(Ⅰ) 또는 그것의 염은 화합물(Ⅷ) 또는 그것의 염을 가수분해 시켜서 제조할 수 있다.Compound (I) or a salt thereof can be prepared by hydrolyzing compound (VII) or a salt thereof.
가수분해는 염기 또는 산 존재하에서 행하는 것이 바람직하다. 적합한 염기에는 알칼리 금속(예를 들면, 나트륨, 칼륨, 등), 그것의 수산화물, 탄산염, 또는 중탄산염, 트리알킬아민(예를 들면, 트리메틸아민, 트리에틸아민, 등), 피콜린, 1,5-디아자바이시클로[4,3,0]는 -5-엔, 1,4-디아자바이시클로[2,2,2]옥탄, 1,8-디아자바이시클로[5,4,0]운데센-7과 같은 무기염기 및 유기염기가 있다. 적합한 산은 유기산(예를 들면, 포름산, 아세트산, 프로피온산, 트리플루오로아세트산) 및 무기산(예를 들면, 염산, 브롬화수소산, 황산 등)이다.Hydrolysis is preferably carried out in the presence of a base or an acid. Suitable bases include alkali metals (eg sodium, potassium, etc.), hydroxides, carbonates, or bicarbonates thereof, trialkylamines (eg trimethylamine, triethylamine, etc.), picoline, 1,5 -Diazabicyclo [4,3,0] is -5-ene, 1,4-diazabicyclo [2,2,2] octane, 1,8-diazabicyclo [5,4,0] Inorganic bases and organic bases such as undecene-7. Suitable acids are organic acids (eg formic acid, acetic acid, propionic acid, trifluoroacetic acid) and inorganic acids (eg hydrochloric acid, hydrobromic acid, sulfuric acid, etc.).
반응은 일반적으로 물, 알코올(예를 들면, 메탄올, 에탄올, 등), 이들의 혼합물 또는 반응에 역영향을 주지 않는 용매중에서 행한다. 액체 염기 또는 산도 용매로서 사용할 수 있다.The reaction is generally carried out in water, alcohols (e.g. methanol, ethanol, etc.), mixtures thereof or solvents which do not adversely affect the reaction. Liquid bases or acids can also be used as solvents.
반응 온도는 한정되지 반응은 않으며 일반적으로 가열하에서 행한다.The reaction temperature is not limited, but the reaction is generally performed under heating.
본 발명은 본 발명의 범위내에서 R1의 보호된 카르복시기 및/또는 시아노기가 반응도중 당해 유리카르복시기로 전환되는 경우도 포함된다. 또한, 필요에 따라서 R1의 카르복시기는 공지 방법에 의해 보호된 카르복시기로 전환될 수 있다.The present invention includes the case where the protected carboxyl group and / or cyano group of R 1 is converted into the free carboxyl group during the reaction within the scope of the present invention. In addition, if necessary, the carboxy group of R 1 may be converted into a protected carboxy group by a known method.
방법 7Method 7
화합물(Ⅴ) 또는 그것의 염은 화합물(ⅩⅡ) 또는 그것의 염의 하이드록시이미노기상에 치환체 첨가반응을 행함으로써 제조할 수 있다.Compound (V) or a salt thereof can be prepared by carrying out a substituent addition reaction on the hydroxyimino group of compound (XII) or a salt thereof.
화합물(ⅩⅡ)의 적합한 염은 알칼리 금속염(예를 들면, 나트륨염, 칼륨염)등이다.Suitable salts of compound (XII) are alkali metal salts (eg sodium salts, potassium salts) and the like.
하이드록시이미노기상의 치환체 첨가반응에 사용되는 시약은 방법 2 와 유사한 방법으로 행할 수 있다. 하이드록시이미노기상의 치환체 첨가반응은 전술한 방법과 유사한 방법으로 행할 수 있다.The reagent used for the substituent addition reaction on the hydroxyimino group can be carried out by a method similar to that in Method 2. Substituent addition reaction on a hydroxy imino group can be performed by the method similar to the above-mentioned method.
본 발명에서, 화합물(Ⅲ), (Ⅳ), (Ⅴ), (Ⅵ) 및 (Ⅷ)은 분리하지 않고 다음 단계에 사용할 수 있다.In the present invention, compounds (III), (IV), (V), (VI) and (iii) can be used in the next step without separation.
목적 화합물(Ⅰ)과 그것의 염은 7-[2-치환된 하이드록시 이미노-2-(5-아미노-1,2,4-티아디아졸-3-일)-아세트아미도]세팔로스포린 화합물을 제조하는데 주요한 중간체로서 유용하며, 이것은 우수한 항박테리아성을 지니고 있고, 7-아미노세팔로스포린화합물을 아실화제인 목적 화합물(Ⅰ), 그것의 반응 유도체 또는 그것의 염과 반응시켜서 제조할 수 있다.The desired compound (I) and salts thereof are 7- [2-substituted hydroxy imino-2- (5-amino-1,2,4-thiadiazol-3-yl) -acetamido] cephalo It is useful as a major intermediate in the preparation of a sporin compound, which has good antibacterial properties and is prepared by reacting a 7-aminocephalosporin compound with the target compound (I), an acylating agent thereof, a reaction derivative thereof, or a salt thereof. Can be.
목적 화합물(Ⅰ) 또는 그것의 염은 출발물질로서 1-알콕시 카르보닐-포름아미딘을 사용하여 제조할 수 있다. 따라서 본 발명의 목적중 하나는 전술한 바와 같이, 화합물(Ⅰ) 또는 그것의 염을 제조하는 새로운 방법을 제공하는 데 있다.The desired compound (I) or salt thereof can be prepared using 1-alkoxy carbonyl-formamidine as starting material. One of the objects of the present invention is therefore to provide a new process for the preparation of compound (I) or a salt thereof, as described above.
본 발명은 상기 새로운 방법이 하기와 같은 관점에서 공지의 방법보다 우수하다는 발견을 기본으로 하고 있다.The present invention is based on the discovery that the new method is superior to known methods in the following aspects.
(1) 공지의 방법은 출발물질, 즉 1-알콕시카르보닐-포름아미딘을 시판 화합물로 부터 제조하는 여러 단계가 필요한 반면, 새로운 방법의 출불 물질은 그 자체가 시판 화합물이므로 공지된 방법은 새로운 방법보다 긴 단계를 필요로 한다.(1) Known methods require several steps to prepare starting materials, i.e., 1-alkoxycarbonyl-formamidine, from commercially available compounds, while the new methods of dispatching materials themselves are commercially available compounds. It requires longer steps than the method.
(2) 공지의 방법은 반응중 고가임과 동시에 위험성이 높은 시약을 필요로 하는 반면, 신규의 방법은 전술한 고가의 위험성이 높은 시약이 필요하지 않기 때문에, 공업용으로서는 신규의 방법이 공지의 방법보다 더욱 바람직하며 안전한 방법이다.(2) Known methods require reagents that are both expensive during the reaction and high in risk, while the new methods do not require the high-risk reagents described above. Even more desirable and safe way.
다음은 실시예에 의거하여 본 발명을 설명하며, 이들은 설명을 목적으로 하는 것이다.The following describes the present invention based on the examples, which are for the purpose of explanation.
[실시예 1]Example 1
물(268ml)중의 2-시아노아세트아미드(67.0g)과 아질산 나트륨(66.1g)의 혼합물에 얼음배스중의 냉각 및 교반하의 10° 내지 15℃에서 아세트산(95.8g)을 적가하고, 그 온도에서 3시간 동안 유지시켰다.To a mixture of 2-cyanoacetamide (67.0 g) and sodium nitrite (66.1 g) in water (268 ml) was added dropwise acetic acid (95.8 g) at 10 ° C. to 15 ° C. under cooling and stirring in an ice bath. Was maintained for 3 hours.
2-시아노-2-하이드록시이미노 아세트 아미드를 포함하는 혼합물은 4N-수산화나트륨 수용액(350ml)로 pH를 8.5로 조절한 후 디에틸설페이트(147.5g)을 첨가하였다.The mixture containing 2-cyano-2-hydroxyimino acetamide was adjusted to pH 8.5 with 4N aqueous sodium hydroxide solution (350 ml), followed by addition of diethyl sulfate (147.5 g).
이 혼합물을 45 내지 50℃에서 1시간동안 교반하고, 가열중에는 4N의 수산화나트륨 수용액을 pH 8.5로 유지하였다.The mixture was stirred at 45-50 [deg.] C. for 1 hour, while maintaining 4N aqueous sodium hydroxide solution at pH 8.5 during heating.
혼합물을 얼음 배스에서 냉각하여 침전물을 수집한 후, 냉수로 세척 및 건조시켜서 2-시아노-2-에톡시이미노 아세트아미드(70.0g)을 얻었다. 융점 125-127℃.The mixture was cooled in an ice bath to collect the precipitate, then washed with cold water and dried to give 2-cyano-2-ethoxyimino acetamide (70.0 g). Melting point 125-127 ° C.
IR(Nujol) : 3400, 3300, 3180, 1705, 1600, 1560, 1160, 1045cm-1 IR (Nujol): 3400, 3300, 3180, 1705, 1600, 1560, 1160, 1045cm -1
NMR(DMSO-d6, δ) : 137(3H, t,J=8Hz), 4.53(2H, q,J=8Hz), 7.93(2H,s).NMR (DMSO-d 6 , δ): 137 (3H, t, J = 8 Hz), 4.53 (2H, q, J = 8 Hz), 7.93 (2H, s).
[실시예 2]Example 2
1,2-디클로-에탄(283ml)중의 2-시아노-2-에톡시이미노 아세트아미드(65.0g) 및 포스포닐 클로라이드(141.5g)의 혼합물을 교반하에서 9시간 동안 환류시켰다. 이 혼합물을 냉각하고 냉각수(1 ℓ )에 혼합하였다.A mixture of 2-cyano-2-ethoxyimino acetamide (65.0 g) and phosphonyl chloride (141.5 g) in 1,2-dichloro-ethane (283 ml) was refluxed for 9 hours under stirring. This mixture was cooled and mixed in chilled water (1 L).
유기층을 분리 제거하고 수세한 후, 무수 마그네슘 황산염으로 건조하고 농축시켜서 오일상 물질(74.7g)을 얻었다.The organic layer was separated, washed with water, dried over anhydrous magnesium sulfate and concentrated to give an oily substance (74.7 g).
오일상 물질을 진공 증류에 의해 정제하여 무색 오일상의 2-에톡시-이미노프로판 디니트릴(57.8g)을 얻었다. 13mmHg에서의 비점. 65 내지 67℃.The oily material was purified by vacuum distillation to give a colorless oily 2-ethoxy-iminopropane dinitrile (57.8 g). Boiling point at 13 mmHg. 65 to 67 ° C.
IR(Film) : 3000, 2250, 1520, 1390, 1250, 1170, 1060, 785cm-1 IR (Film): 3000, 2250, 1520, 1390, 1250, 1170, 1060, 785cm -1
NMR(CDCl3, δ) : 1.43(3H,t,J=7Hz), 4.67(2H,q,J=7Hz).NMR (CDCl 3 , δ): 1.43 (3H, t, J = 7 Hz), 4.67 (2H, q, J = 7 Hz).
[실시예 3]Example 3
실시예 1 및 2와 유사한 방법으로 하기화합물을 얻었다.In the same manner as in Examples 1 and 2, the following compounds were obtained.
(1) 2-시아노메톡시이미노프로판디니트릴, 5mmHg애서의 비점. 90-105℃.(1) Boiling point of 2-cyanomethoxyiminopropanedinitrile in 5 mmHg. 90-105 ° C.
IR(Film) : 3050, 2950, 2250, 1550, 1430, 1250, 1060cm-1 IR (Film): 3050, 2950, 2250, 1550, 1430, 1250, 1060cm -1
(2) 2-메톡시이미노프로판디니트릴, 12mmHg애서의 비점. 47-48℃.(2) The boiling point of 2-methoxyiminopropanedinitrile in 12 mmHg. 47-48 ° C.
IR(Film) : 3030, 2980, 2260, 1528, 1455, 1395cm-1 IR (Film): 3030, 2980, 2260, 1528, 1455, 1395cm -1
(3) 2-(2-프로피닐옥시이미노)프로판디니트릴(3) 2- (2-propynyloxyimino) propanedinitrile
IR(Film) : 3320, 2960, 2250, 2150, 1532, 1438cm-1 IR (Film): 3320, 2960, 2250, 2150, 1532, 1438cm -1
(4) 2-알릴옥시이미노프로판디니트릴(4) 2-allyloxyiminopropanedinitrile
IR(Film) : 2220, 1520, 1420, 1350, 1242, 1050cm-1 IR (Film): 2220, 1520, 1420, 1350, 1242, 1050cm -1
(5) 2-메톡시카르보닐메톡시이미노프로판디니트릴, 5.5mmHg에서의 비점 90-99℃.(5) 2-methoxycarbonylmethoxyiminopropanedinitrile, boiling point 90-99 ° C. at 5.5 mmHg.
IR(Film) : 3050, 3000, 2250, 1765, cm-1 IR (Film): 3050, 3000, 2250, 1765, cm -1
[실시예 4]Example 4
아세토니트릴(225ml)중의 2-하이드록시-이미노프로판 디니트릴의 나트륨염(45g), 메틸 클로로아세테이트(41.8g) 및 요오드화 나트륨(5.8g)의 혼합물을 50℃에서 3시간동안 교반한 후, 실온에서 하룻밤 동안 정치시켰다.After stirring a mixture of sodium salt of 2-hydroxy-iminopropane dinitrile (45 g), methyl chloroacetate (41.8 g) and sodium iodide (5.8 g) in acetonitrile (225 ml) for 3 hours, It was allowed to stand overnight at room temperature.
반응 혼합물을 증발시킨 후 잔사를 디이소프로필 에테르화 물의 혼합물에 용해시켰다.After evaporation of the reaction mixture the residue was dissolved in a mixture of diisopropyl etherified water.
유기층을 분리 제거하고 수세한 후, 황산 마그네슘으로 건조하고 증발 시켜서 2-메톡시카르보닐메톡시이미노프로판디니트릴의 미정제 오일(45.0g)을 얻었으며, 이것을 증류에 의해 정제하였다. 5.5mmHg 에서의 비점 90-99℃.The organic layer was separated, washed with water, dried over magnesium sulfate and evaporated to obtain crude oil (2-5.0 g) of 2-methoxycarbonylmethoxyiminopropanenitrile, which was purified by distillation. Boiling point 90-99 ° C. at 5.5 mmHg.
IR(Film) : 3050, 3000, 2250, 1765Cm-1 IR (Film): 3050, 3000, 2250, 1765Cm -1
[실시예 5]Example 5
(1) 하기의 화합물은 실시예 4 와 유사한 방법으로 2-하이드록시이미노프로판디니트릴의 나트륨과 클로로아세트 니트릴을 반응시켜서 제조하였다.(1) The following compound was prepared by reacting sodium and chloroacetnitrile of 2-hydroxyiminopropanedinitrile in a similar manner to Example 4.
2-시아노메톡시이미노프로판디니트릴, 5mmHg에서의 비점 90-105℃.2-cyanomethoxyiminopropanedinitrile, boiling point 90-105 degreeC in 5 mmHg.
IR(Film) : 3050, 2950, 2250, 1550, 1430, 1250, 1060cm-1 IR (Film): 3050, 2950, 2250, 1550, 1430, 1250, 1060cm -1
(2) 하기의 화합물은 실시예 4 와 유사한 방법으로 2-하이드록시 아미노프로판디니트릴의 나트륨염을 디메틸 설페이트와 반응시켜서 제조하였다.(2) The following compound was prepared by reacting the sodium salt of 2-hydroxy aminopropanedinitrile with dimethyl sulfate in a similar manner as in Example 4.
2-메톡시이미노프로판디니트릴, 12mmHg 에서의 비점 47-48℃.2-methoxyiminopropanedinitrile, boiling point 47-48 ° C. at 12 mm Hg.
IR(Film) : 3030, 2980, 2260, 1528, 1455, 1395cm-1 IR (Film): 3030, 2980, 2260, 1528, 1455, 1395cm -1
(3) 하기의 화합물은 실시예 4 와 유사한 방법으로 2-하이드록시 이미노프로판디니트릴의 나트륨염과 2-프로피닐브로마이드와 반응시켜서 제조하였다.(3) The following compound was prepared by reacting the sodium salt of 2-hydroxy iminopropanedinitrile with 2-propynylbromide in a similar manner to Example 4.
2-(2-프로피닐옥시이미노)프로판디니트릴2- (2-propynyloxyimino) propanedinitrile
IR(Film) : 3320, 2960, 2250, 2150, 1532, 1438cm-1 IR (Film): 3320, 2960, 2250, 2150, 1532, 1438cm -1
NMR(CDCl3, δ) : 2.72(1H,t,3Hz), 5.10(2H,d,J=3Hz).NMR (CDCl 3 , δ): 2.72 (1H, t, 3 Hz), 5.10 (2H, d, J = 3 Hz).
(4) 하기의 화합물은 실시예 4 와 유사한 방법으로 2-하이드록시 이미노프로판디니트릴의 나트륨염과 알릴브로마이드을 반응시켜서 제조하였다.(4) The following compound was prepared by reacting allyl bromide with sodium salt of 2-hydroxy iminopropanedinitrile in a similar manner to Example 4.
2-알릴옥시이미노프로판디니트릴2-allyloxyiminopropanedinitrile
IR(Film) : 2220, 1520, 1420, 1350, 1242, 1050cm-1 IR (Film): 2220, 1520, 1420, 1350, 1242, 1050cm -1
NMR(CCl4,δ) : 4.97(2H,d,J=6Hz). 5.3-5.6(2H,m), 5.6-6.3(1H,m).NMR (CCl 4, δ): 4.97 (2H, d, J = 6 Hz). 5.3-5.6 (2H, m), 5.6-6.3 (1H, m).
(5) 하기의 화합물은 실시예 4 와 유사한 방법에 따라 제조하였다.(5) The following compound was prepared in a similar manner to Example 4.
2-에톡시이미노프로판디니트릴, 13mmHg에서의 비점 65-67℃.2-ethoxyiminopropanedinitrile, boiling point 65-67 ° C. at 13 mmHg.
IR(Film) : 3000, 2250, 1520, 1390, 1250, 1170, 1060, 785cm-1 IR (Film): 3000, 2250, 1520, 1390, 1250, 1170, 1060, 785cm -1
[실시예 6]Example 6
(1) 에탄올(20ml)중의 암모늄 클로라이드(3.2g)과 수산화암모늄 농축수용액(20ml)의 용액에 교반하의 -5°~0℃에서 2-에톡시이미노 프로판디니트릴(3.7g)을 첨가하고, 이 온도에서 1시간 30분간 동안 유지시켰다. 혼합물은 물(40ml)와 메틸렌 클로라이드(40ml)의 혼합물로 희석하였다. 유기층을 분리 제거하고, 수층을 메틸렌 클로라이드(20ml)로 2회 추출하였다. 이 유기층을 혼합하고 무수마그네슘 설페이트로 건조시킨 후, 증발건조 시켰다. 잔사를 석유 에테르로 연화시켜서 m.p.110°-111℃인 2-시아노-에톡시이미노아세트아미딘(2.4g)을 얻었다.(1) To a solution of ammonium chloride (3.2 g) and concentrated aqueous ammonium hydroxide solution (20 ml) in ethanol (20 ml) was added 2-ethoxyimino propanedinitrile (3.7 g) at −5 ° to 0 ° C. under stirring, It was kept at this temperature for 1 hour 30 minutes. The mixture was diluted with a mixture of water (40 ml) and methylene chloride (40 ml). The organic layer was separated and the aqueous layer was extracted twice with methylene chloride (20 ml). The organic layer was mixed, dried over anhydrous magnesium sulfate, and evaporated to dryness. The residue was triturated with petroleum ether to give 2-cyano-ethoxyiminoacetamine (2.4 g) which was m.p. 110 ° -111 ° C.
IR(Nujol) : 3450, 3280, 2250, 1655, 1620, 1600, 1220, 1045cm-1 IR (Nujol): 3450, 3280, 2250, 1655, 1620, 1600, 1220, 1045cm -1
NMR(CD2OD, δ) : 1.40(3H,t,J=7Hz), 4.50(2H,q,J=7Hz).NMR (CD 2 OD, δ): 1.40 (3H, t, J = 7 Hz), 4.50 (2H, q, J = 7 Hz).
(2) 암모늄염(159g), 수산화암모늄 농축 수용액(2ℓ)과 에탄올(900ml)의 혼합물에 교반하의 -15° 내지 -10℃에서 1시간 30분 동안 에탄올(600ml)중의 2-메톡시 이미노프로판디니트릴(325g)의용액을 첨가하고 30분동안 유지시켰다.(2) 2-methoxy iminopropane in ethanol (600 ml) for 1 hour and 30 minutes at -15 ° to -10 ° C with stirring to a mixture of ammonium salt (159 g), concentrated aqueous solution of ammonium hydroxide (2 L) and ethanol (900 ml). A solution of dinitrile (325 g) was added and held for 30 minutes.
반응 혼합물을 메틸렌 클로라이드(2ℓ)와 물(2ℓ)의 혼합물에 혼합하였다. 유기층을 분리 제거하고, 수층은 염을 제거한 후 메틸렌 클로라이드로 추출하였다. 유기층과 추출물을 혼합하여 마그네슘설페이트로 건조시킨 후 증발시켰다. 잔사 오일을 에틸 아세테이트(7ℓ)에 용해하고, 빙초산(77.6g)을 교반하에 적가하였다.The reaction mixture was mixed with a mixture of methylene chloride (2 L) and water (2 L). The organic layer was separated and the aqueous layer was removed with salt and extracted with methylene chloride. The organic layer and the extract were mixed, dried over magnesium sulfate, and evaporated. The residue oil was dissolved in ethyl acetate (7 L) and glacial acetic acid (77.6 g) was added dropwise under stirring.
생성된 침전물을 수집하고, 에틸 아세테이트로 세정한 후 건조시켜서 2-시아노-2-메톡시이미노아세트아미딘 아세테이트(160.77g)을 얻었다. m.p.150°-155℃(분해).The resulting precipitate was collected, washed with ethyl acetate and dried to give 2-cyano-2-methoxyiminoacetamide acetate (160.77 g). m.p. 150 ° -155 ° C. (decomposition).
IR(Nujol) : 3250, 2700, 2350, 2250, 1675, 1580, 1548, 1530, 1495cm-1 IR (Nujol): 3250, 2700, 2350, 2250, 1675, 1580, 1548, 1530, 1495 cm -1
NMR(DMSO-d6, δ) : 1.90(3H,s), 4.17(3H,s), 7.65(4H,s).NMR (DMSO-d 6 , δ): 1.90 (3H, s), 4.17 (3H, s), 7.65 (4H, s).
(3) 교반하에서 메탄올(10ml)중의 암모늄 아세테이트(4.62g) 용액에 2-메톡시카르보닐-메톡시이미노프로판디니트릴(3.34g)을 첨가하고, 실온에서 2시간 동안 유지시킨 후, 하룻밤 동안 정지시켰다.(3) To a solution of ammonium acetate (4.62 g) in methanol (10 ml) under stirring was added 2-methoxycarbonyl-methoxyiminopropanedinitrile (3.34 g), held at room temperature for 2 hours, and then overnight Stopped.
이 반응 혼합물에 이소프로필알코올(15ml)을 첨가하고 15분 동안 교반하였다.Isopropyl alcohol (15 ml) was added to the reaction mixture and stirred for 15 minutes.
생성된 침전물을 여과하여 수집하고 이소프로필 알코올로 세정한 후 건조시켜서 2-시아노-2-메톡시카르보닐메톡시이미노-아세트아미딘 아세테이트(3.4g)을 얻었으며, 이것을 메탄올로 재결정화시켰다. m.p.157°-158℃(분해).The resulting precipitate was collected by filtration, washed with isopropyl alcohol and dried to give 2-cyano-2-methoxycarbonylmethoxyimino-acetamide acetate (3.4 g), which was recrystallized from methanol. . m.p. 157 ° -158 ° C. (decomposition).
IR(Nujol) : 2800-2200, 1750, 1680, 1550cm-1 IR (Nujol): 2800-2200, 1750, 1680, 1550cm -1
NMR(DMSO-d6, δ) : 1.90(3H,s), 3.73(3H,s), 5.10(2H,s), 7.0-7.5(4H, broad, s).NMR (DMSO-d 6 , δ): 1.90 (3H, s), 3.73 (3H, s), 5.10 (2H, s), 7.0-7.5 (4H, broad, s).
[실시예 7]Example 7
하기의 화합물들은 실시예 6 과 유사한 방법으로 제조하였다.The following compounds were prepared in a similar manner to Example 6.
(1) 2-시아노-2-프로피닐옥시이미노 아세트아미딘 mp.78℃.(1) 2-cyano-2-propynyloxyimino acetamidine mp.78 ° C.
IR(Nujol) : 3450, 3330, 3220, 3110, 2220, 1650, 1645, 1635cm-1 IR (Nujol): 3450, 3330, 3220, 3110, 2220, 1650, 1645, 1635 cm -1
NMR(CDCl3+D2O, δ) : 4.90(2H,d,J=5Hz), 5.2-5.7(2H,m), 5.7-6.3(1H,m).NMR (CDCl 3 + D 2 O, δ): 4.90 (2H, d, J = 5 Hz), 5.2-5.7 (2H, m), 5.7-6.3 (1H, m).
(2) 2-시아노-2-(2-프로피닐옥시이미노)아세트아미딘, mp. 105-108℃(분해).(2) 2-cyano-2- (2-propynyloxyimino) acetamidine, mp. 105-108 ° C. (decomposition).
IR(Nujol) : 3450, 3270, 3150, 2210, 2100, 1630, 1560, 1420cm-1 IR (Nujol): 3450, 3270, 3150, 2210, 2100, 1630, 1560, 1420cm -1
NMR(CDCL_, δ) : 2.63(1H,t,J=3Hz), 4.95(2H,d,J=3Hz), 5.83(3H, broad, s).NMR (CDCL ′, δ): 2.63 (1H, t, J = 3 Hz), 4.95 (2H, d, J = 3 Hz), 5.83 (3H, broad, s).
(3) 2-시아노-2-시아노메톡시이모아세트아미딘, mp60-46℃.(3) 2-cyano-2-cyanomethoxyimomoacetamine, mp60-46 ° C.
IR(Nujol) : 3450, 3300, 3150, 1640, 1600, 1570cm-1 IR (Nujol): 3450, 3300, 3150, 1640, 1600, 1570cm -1
[실시예 8]Example 8
(1) 메탄올(120ml)중의 2-시아노-2-에톡시이미노아세트 아미딘(8.0g)과 트리에틸아민(11.5g)의 용액에 교반하의 -10℃에서 브롬(9.1g)을 적가하고, -10 내지 -5℃에서 수분동안 유지시켰다.(1) To a solution of 2-cyano-2-ethoxyiminoacet amidine (8.0 g) and triethylamine (11.5 g) in methanol (120 ml) was added dropwise bromine (9.1 g) at -10 deg. And maintained at -10? -5 占 폚 for a few minutes.
이 반응 혼합물에 교반하의 -10°―5℃에서 메탄올(55ml)중의 칼륨 티오시아네이트(5.5g)의 용액을 적가하고 0°~5℃에서 2시간 동안 유지시켰다.To the reaction mixture was added dropwise a solution of potassium thiocyanate (5.5 g) in methanol (55 ml) at −10 ° -5 ° C. under stirring and maintained at 0 ° -5 ° C. for 2 hours.
생성된 침전물은 여과하고, 메탄올과 물로세정한 후, 건조시켜서 2-메톡시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일)아세토니트릴의 갈색분말(syn 이성체)(10.15g)을 얻었다. m.p.270°-273℃(분해).The resulting precipitate was filtered, washed with methanol and water and dried to give a brown powder of 2-methoxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetonitrile (syn Isomers) (10.15 g). m.p. 270 ° -273 ° C. (decomposition).
IR(Nujol) : 3400, 3260, 3150, 2250, 1620, 1540, 1190, 1040cm-1 IR (Nujol): 3400, 3260, 3150, 2250, 1620, 1540, 1190, 1040cm -1
NMR(DMSO-d6, δ) : 1.37(3H,t,J=7Hz), 4.50(2H,q,J=7Hz), 8.37(2H,s).NMR (DMSOd 6 , δ): 1.37 (3H, t, J = 7 Hz), 4.50 (2H, q, J = 7 Hz), 8.37 (2H, s).
(2) 메탄올(4.95ℓ)중의 2-시아노-2-메톡시카르보닐-메톡시이미노아세트아미딘 아세테이트(495g)의 현탁액에 교반 및 냉각하의 -10℃에서 트리에틸아민(512.6g)을 적가하고, 브롬(357.3g)을 같은 온도에서 상기 혼합물에 첨가하였다. 반응 혼합물을 15분간 교반한 후, 메탄올(2.16)중의 칼륨 티오시아네이트(216g)의 용액을 교반하에 -10°~-5℃에서 적가하고, 0 내지 5℃에서 30분 동안 유지시켰다.(2) To a suspension of 2-cyano-2-methoxycarbonyl-methoxyiminoacetamide acetate (495 g) in methanol (4.95 L) triethylamine (512.6 g) at −10 ° C. under stirring and cooling. Was added dropwise and bromine (357.3 g) was added to the mixture at the same temperature. After the reaction mixture was stirred for 15 minutes, a solution of potassium thiocyanate (216 g) in methanol (2.16) was added dropwise at -10 ° to -5 ° C under stirring, and maintained at 0 to 5 ° C for 30 minutes.
생성된 침전물을 여과하여 수집하고, 물(5ℓ)로 세정한 후 건조시켜서 2-메톡시 카르보닐메톡시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일)아세토니트릴(syn 이서체)430g을 얻었으며, 수성 메탄올로 재결정화 하였다. m.p. 225°-227℃(분해).The resulting precipitate was collected by filtration, washed with water (5 L) and dried to give 2-methoxy carbonylmethoxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl). 430 g of acetonitrile (syn isomer) were obtained and recrystallized from aqueous methanol. m.p. 225 ° -227 ° C. (decomposition).
IR(Nujol) : 3400, 3250, 3100, 1740, 1630, 1550cm-1 IR (Nujol): 3400, 3250, 3100, 1740, 1630, 1550cm -1
NMR(DMSO-d6, δ) : 3.77(3H, s), 5.17(2H, s), 8.33(2H, s)NMR (DMSO-d 6 , δ): 3.77 (3H, s), 5.17 (2H, s), 8.33 (2H, s)
[실시예 9]Example 9
하기의 화합물은 실시예 8 과 유사한 방법으로 제조하였다.The following compounds were prepared in a similar manner to Example 8.
(1) 2-메톡시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일)아세토니트릴(syn 이성체),mp. 210~215℃(분해).(1) 2-methoxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetonitrile (syn isomer), mp. 210-215 degreeC (decomposition).
IR(Nujol) : 3460, 3270, 3140, 2260, 1632, 1540cm-1 IR (Nujol): 3460, 3270, 3140, 2260, 1632, 1540cm -1
NMR(DMSO-d6, δ) : 4.24(3H,s), 8.32(2H,s).NMR (DMSO-d 6 , δ): 4.24 (3H, s), 8.32 (2H, s).
(2) 2-(2-프로피닐옥시이미노)-2-(5-아미노-1,2,4-티아디아졸-3-일)아세토니트릴(syn 이성체),mp. 193~195℃(분해).(2) 2- (2-propynyloxyimino) -2- (5-amino-1,2,4-thiadiazol-3-yl) acetonitrile (syn isomer), mp. 193-195 degreeC (decomposition).
IR(Nujol) : 3460, 3270, 3180, 3160, 2690, 2150, 1625, 1560, 1538cm-1 IR (Nujol): 3460, 3270, 3180, 3160, 2690, 2150, 1625, 1560, 1538 cm -1
NMR(DMSO-d6δ) : 3.70(1H,t,J=7Hz), 5.12(2H,d,J=7Hz), 8.35(2H, broad s).NMR (DMSO-d 6 δ): 3.70 (1H, t, J = 7 Hz), 5.12 (2H, d, J = 7 Hz), 8.35 (2H, broad s).
(3) 2-알릴옥시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일)아세토니트릴(syn 이성체),mp. 180~184℃(분해).(3) 2-allyloxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetonitrile (syn isomer), mp. 180-184 ° C. (decomposition).
IR(Nujol) : 3430, 3260, 3140, 2220, 1625, 1540cm-1 IR (Nujol): 3430, 3260, 3140, 2220, 1625, 1540cm -1
NMR(DMSO-d6, δ) : 4.90(2H,d,J=6Hz), 5.1-5.6(2H,m), 5.7-6.4(1H,m), 8.27(2H,s).NMR (DMSO-d 6 , δ): 4.90 (2H, d, J = 6 Hz), 5.1-5.6 (2H, m), 5.7-6.4 (1H, m), 8.27 (2H, s).
(4)2-시아노메톡시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일)아세토니트릴(syn 이성체),mp. 190~195℃(분해).(4) 2-cyanomethoxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetonitrile (syn isomer), mp. 190-195 ° C. (decomposition).
IR(Nujol) : 3450, 3300, 3150, 1630, 1540cm-1 IR (Nujol): 3450, 3300, 3150, 1630, 1540cm -1
[실시예 10]Example 10
(1) 물(142ml)중의 2-에톡시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세토니트릴(syn 이성체)(10.g)과 수산화나트륨 (22.8g)의 혼합액을 50°-55℃에서 5시간 동안 교반하였다.(1) 2-ethoxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetonitrile (syn isomer) (10.g) and sodium hydroxide in water (142 ml) 22.8 g) of the mixed solution was stirred at 50 ° -55 ° C for 5 hours.
반응혼합물을 냉각시키고, 6N-염산으로 pH 1로 조절한 후 에틸아세테이트(50ml)로 3회 추출하였다.The reaction mixture was cooled, adjusted to pH 1 with 6N hydrochloric acid and extracted three times with ethyl acetate (50 ml).
추출물을 혼합하여 무수 마그네슘 설페이트로 건조시킨후 증발 건조시켰다. 잔사를 에틸아세테이트로 재결화하여 미세한 침상의 2-에톡시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일)아세트산(syn 이성체)(8.2g)을 얻었다. m.p. 187℃(분해)The extract was mixed, dried over anhydrous magnesium sulfate and evaporated to dryness. The residue was recrystallized with ethyl acetate to obtain fine needle-like 2-ethoxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer) (8.2 g). m.p. 187 ° C (decomposition)
IR(Nujol) : 3450, 3250, 3150, 1720, 1620, 1535, 1040, 1010cm-1 IR (Nujol): 3450, 3250, 3150, 1720, 1620, 1535, 1040, 1010 cm -1
NMR(DMSO-d6δ) : 1.23(3H, t, J=7Hz), 4.22(2H, q, J=7Hz),8.17(2H, s)NMR (DMSO-d 6 δ): 1.23 (3H, t, J = 7 Hz), 4.22 (2H, q, J = 7 Hz), 8.17 (2H, s)
(2) 물(8.36ℓ)중의 수산화나트륨(334.5g) 용액에 실온에서 2-메톡시카르보닐메톡시-이미노-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세토니트릴(syn 이성체)(550g)을 첨가하고, 이 혼합물을 60°-65℃에서 5시간 동안 교반하였다. 반응 혼합물은 아이스 배스상에서 냉각시키고, 50% 황산 수용액으로 pH 3.0으로 조절한 후 에틸아세테이트로 세정하였다. 수용액은 염석시킨 후, 50% 황산 수용액으로 pH 1.0으로 조절하여 아세토니트릴(6×2.5ℓ)로 추출하였다. (추출물 A)(2) 2-methoxycarbonylmethoxy-imino-2- (5-amino-1,2,4-thiadiazole-3- in a solution of sodium hydroxide (334.5 g) in water (8.36 L) at room temperature I) Acetonitrile (syn isomer) (550 g) was added and the mixture was stirred at 60 ° -65 ° C. for 5 hours. The reaction mixture was cooled on an ice bath, adjusted to pH 3.0 with 50% aqueous sulfuric acid solution and washed with ethyl acetate. The aqueous solution was salted out, adjusted to pH 1.0 with 50% aqueous sulfuric acid solution, and extracted with acetonitrile (6 × 2.5 L). (Extract A)
추출물 A는 마그네슘 설페이트(10kg)으로 건조 시킨후 여과하였다. 교반하에서 여과물에 메탄올(1.2ℓ)중의 나트륨 아세테이트(109g)의 용액을 첨가한 후, 15분동안 유지시켰다.Extract A was dried over magnesium sulfate (10 kg) and filtered. Under stirring, a solution of sodium acetate (109 g) in methanol (1.2 L) was added to the filtrate and held for 15 minutes.
생성된 침전물을 여과하여 수집하고 아세토니트릴과 디이소프로필에테르로 세정한 후 건조시켜서 나트륨-2-카르복시메톡시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세테이트(syn 이성체)(342.8g)을 얻었다. m.p. 155°-160℃(분해)The resulting precipitate was collected by filtration, washed with acetonitrile and diisopropyl ether and dried to give sodium-2-carboxymethoxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl. ) Acetate (syn isomer) (342.8 g) was obtained. m.p. 155 ° -160 ° C (decomposition)
IR(Nujol) : 3320, 3180, 1720, 1630, 1530cm-1 IR (Nujol): 3320, 3180, 1720, 1630, 1530cm -1
NMR(DMSO-d6, δ) : 4.48(2H, s), 8.08(2H, broad s)NMR (DMSO-d 6 , δ): 4.48 (2H, s), 8.08 (2H, broad s)
상기에서 얻은 추출물 A는 증발 건조시켰다. 메탄올로 재결정화시켜서 2-카르복시메톡시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일) 초산(syn 이성체)를 얻었다.Extract A obtained above was evaporated to dryness. Recrystallization with methanol gave 2-carboxymethoxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer).
m.p. 193°-194℃(분해)m.p. 193 ° -194 ° C (decomposition)
IR(Nujol) : 3400, 3250, 3100, 2800-2200, 1730, 1630, 1540cm-1 IR (Nujol): 3400, 3250, 3100, 2800-2200, 1730, 1630, 1540cm -1
NMR(DMSO-d6, δ) : 4.65(2H, s), 8.15(2H, s)NMR (DMSO-d 6 , δ): 4.65 (2H, s), 8.15 (2H, s)
C6H6N4O5S의 분석 계산치 : C 29.27, H 2.46 N 22.76Analytical calculation for C 6 H 6 N 4 O 5 S: C 29.27, H 2.46 N 22.76
실측치 : C 29.18, H 2.58 N 22.09Found: C 29.18, H 2.58 N 22.09
출발 화합물로서 2-메톡시카르보닐메톡시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일)아세토니트릴(syn 이성체) 대신에 2-시아노메톡시-이미노-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세토니트릴(syn 이성체)를 사용하여 상기와 유사한 방법에 의해 동일한 목적 화합물을 얻었다.2-cyanomethoxy-imino instead of 2-methoxycarbonylmethoxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetonitrile (syn isomer) as starting compound The same target compound was obtained by a method similar to the above using 2- (5-amino-1,2,4-thiadiazol-3-yl) acetonitrile (syn isomer).
[실시예 11]Example 11
하기의 화합물들은 실시예 1,2,6,8 및 10 또는 실시예 4,6,8 및 10과 유사한 방법에 의해 얻었다.The following compounds were obtained by methods analogous to Examples 1,2,6,8 and 10 or Examples 4,6,8 and 10.
(1) 2-(2-시클로헥센-1-일) 옥시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 173℃.(1) 2- (2-cyclohexen-1-yl) oxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 173 ° C.
IR(Nujol) : 3400, 3300, 3200, 1720, 1620, 1600, 1520cm-1 IR (Nujol): 3400, 3300, 3200, 1720, 1620, 1600, 1520cm -1
NMR(DMSO-d6, δ) : 1.50-2.17(6H, m), 4.53-4.83(1H, m), 5.57-6.13(2H, m), 8.18(2H, s)NMR (DMSO-d 6 , δ): 1.50-2.17 (6H, m), 4.53-4.83 (1H, m), 5.57-6.13 (2H, m), 8.18 (2H, s)
(2) 2-시클로펜텐옥시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 160~165℃ (분해).(2) 2-cyclopenteneoxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 160-165 ° C. (decomposition).
IR(Nujol) : 3470, 3290, 3200, 2400, 1715, 1615, 1600, 1520cm-1 IR (Nujol): 3470, 3290, 3200, 2400, 1715, 1615, 1600, 1520 cm -1
NMR(DMSO-d6, δ) : 1.17-2.10(8H, m), 4.60-4.97(1H, m), 8.22(2H, s)NMR (DMSO-d 6 , δ): 1.17-2.10 (8H, m), 4.60-4.97 (1H, m), 8.22 (2H, s)
(3) 2-시클로헵틸옥시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 116~119℃ (분해).(3) 2-cycloheptyloxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 116-119 degreeC (decomposition).
IR(Nujol) : 3250, 3200, 1650, 1600, 1520, 1400, 1260, 1150, 1000, 820, 720cm-1 IR (Nujol): 3250, 3200, 1650, 1600, 1520, 1400, 1260, 1150, 1000, 820, 720cm -1
(4) 2-메실메톡시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체).(4) 2-methylmethoxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer).
IR(Nujol) : 3450, 3400, 3270, 2600, 2460, 1735, 1640, 1620, 1530cm-1 IR (Nujol): 3450, 3400, 3270, 2600, 2460, 1735, 1640, 1620, 1530 cm -1
NMR(d6-DMSO, δ) : 3.00(3H, s), 5.38(2H, s), 8.22(2H, broad S)NMR (d 6 -DMSO, δ): 3.00 (3H, s), 5.38 (2H, s), 8.22 (2H, broad S)
(5) 2-알릴옥시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 93~95℃ (분해).(5) 2-allyloxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 93-95 ° C. (decomposition).
IR(Nujol) : 3430, 3100, 1710, 1615, 1525cm-1 IR (Nujol): 3430, 3100, 1710, 1615, 1525cm -1
NMR(d6-DMSO, δ) : 4.72(2H, d, J=6Hz), 5.1-5.5(2H, m), 5.7-6.3(1H, m), 8.17(1H, broad s)NMR (d 6 -DMSO, δ): 4.72 (2H, d, J = 6 Hz), 5.1-5.5 (2H, m), 5.7-6.3 (1H, m), 8.17 (1H, broad s)
(6) 2-벤질옥시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일)아세트산 (syn 이성체), mp. 158~160℃ (분해).(6) 2-benzyloxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 158-160 degreeC (decomposition).
IR(Nujol) : 3430, 3380, 3260, 1730, 1640, 1610, 1535cm-1 IR (Nujol): 3430, 3380, 3260, 1730, 1640, 1610, 1535cm -1
NMR(d6-DMSO, δ) : 5.22(2H, s), 7.38(5H, s), 8.17(2H, broad s)NMR (d 6 -DMSO, δ): 5.22 (2H, s), 7.38 (5H, s), 8.17 (2H, broad s)
(7) 2-(2-프로피닐옥시이미노)-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 155~157℃ (분해).(7) 2- (2-propynyloxyimino) -2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 155-157 ° C. (decomposition).
IR(Nujol) : 3500, 3310, 3160, 2600, 2480, 1745, 1610, 1535cm-1 IR (Nujol): 3500, 3310, 3160, 2600, 2480, 1745, 1610, 1535cm -1
NMR(d6-DMSO, δ) : 3.53(1H, t, J=2Hz), 4.87(2H, d, J=2Hz), 8.23(2H, broad s)NMR (d 6 -DMSO, δ): 3.53 (1H, t, J = 2 Hz), 4.87 (2H, d, J = 2 Hz), 8.23 (2H, broad s)
(8) 2-(2-펜옥시에톡시이미노)-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 150~153℃ (분해).(8) 2- (2-phenoxyethoxyimino) -2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 150-153 ° C. (decomposition).
IR(Nujol) : 3470, 3300, 3150, 2550, 1750, 1620, 1600, 1540, 1500cm-1 IR (Nujol): 3470, 3300, 3150, 2550, 1750, 1620, 1600, 1540, 1500cm -1
NMR(d6-DMSO, δ) : 4.0-4.7(4H, m), 6.7-7.5(5H, m), 8.20(2H, broad s)NMR (d 6 -DMSO, δ): 4.0-4.7 (4H, m), 6.7-7.5 (5H, m), 8.20 (2H, broad s)
(9) 2-(2,2,2-트리플루오로에톡시이미노)-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 140~0143℃ (분해).(9) 2- (2,2,2-trifluoroethoxyimino) -2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 140-0143 ° C (decomposition).
IR(Nujol) : 3450, 3350, 3260, 1745, 1670, 1645, 1615, 1515cm-1 IR (Nujol): 3450, 3350, 3260, 1745, 1670, 1645, 1615, 1515 cm -1
NMR(d6-DMSO, δ) : 4.72 and 4.95(2H, ABq, J=9Hz), 8.25(2H, broad s)NMR (d 6 -DMSO, δ): 4.72 and 4.95 (2H, ABq, J = 9 Hz), 8.25 (2H, broad s)
(10) 2-메틸티오메톡시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 140~143℃ (분해).(10) 2-methylthiomethoxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 140-143 ° C. (decomposition).
IR(Nujol) : 3500, 3300, 3150, 2670, 2580, 1740, 1615, 1605, 1530cm-1 IR (Nujol): 3500, 3300, 3150, 2670, 2580, 1740, 1615, 1605, 1530 cm -1
NMR(d6-DMSO, δ) : 2.22(3H, s), 5.33(2H, s), 8.20(2H, broad S)NMR (d 6 -DMSO, δ): 2.22 (3H, s), 5.33 (2H, s), 8.20 (2H, broad S)
(11) 2-(2-메틸티오에톡시이미노)-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 140~143℃ (분해).(11) 2- (2-methylthioethoxyimino) -2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 140-143 ° C. (decomposition).
IR(Nujol) : 3430, 3340, 3230, 2650, 2450, 1720, 1610, 1520cm-1 IR (Nujol): 3430, 3340, 3230, 2650, 2450, 1720, 1610, 1520cm -1
NMR(d6-DMSO, δ) : 2.08(3H, s), 2.72(2H, t, J=7Hz), 4.28(2H, t, J=7Hz), 8.17(2H, broad s)NMR (d 6 -DMSO, δ): 2.08 (3H, s), 2.72 (2H, t, J = 7 Hz), 4.28 (2H, t, J = 7 Hz), 8.17 (2H, broad s)
(12) 2-펜옥시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 145~147℃ (분해).(12) 2-phenoxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 145-147 ° C. (decomposition).
IR(Nujol) : 3350, 3170, 2500, 1730, 1710, 1645, 1630, 1595, 1535cm-1 IR (Nujol): 3350, 3170, 2500, 1730, 1710, 1645, 1630, 1595, 1535 cm -1
NMR(d6-DMSO, δ) : 7.0-7.5(5H, m), 8.30(2H, broad s)NMR (d 6 -DMSO, δ): 7.0-7.5 (5H, m), 8.30 (2H, broad s)
(13) 2-[2-(2-헥실옥시에톡시) 에톡시이미노]-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체).(13) 2- [2- (2-hexyloxyethoxy) ethoxyimino] -2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer).
IR(Nujol) : 3350, 3230, 2600, 2500, 1730, 1620, 1520, 1460cm-1 IR (Nujol): 3350, 3230, 2600, 2500, 1730, 1620, 1520, 1460 cm -1
NMR(d6-DMSO, δ) : 0.87(3H, t, J=5Hz), 0.87-1.73(8H, m), 3.20-3.90(8H, m), 4.13-4.47(2H, m), 8.17(2H, broad s)NMR (d 6 -DMSO, δ): 0.87 (3H, t, J = 5 Hz), 0.87-1.73 (8H, m), 3.20-3.90 (8H, m), 4.13-4.47 (2H, m), 8.17 ( 2H, broad s)
(14) 2-트리틸옥시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일)-아세트산 (syn 이성체), mp. 173~174℃ (분해).(14) 2-trityloxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) -acetic acid (syn isomer), mp. 173-174 ° C. (decomposition).
IR(Nujol) : 3450, 1735, 1620, 1540cm-1 IR (Nujol): 3450, 1735, 1620, 1540cm -1
NMR(d6-DMSO, δ) : 7.35(15H, s), 8.22(2H, s)NMR (d 6 -DMSO, δ): 7.35 (15H, s), 8.22 (2H, s)
(15) 2-트리틸옥시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (anti 이성체), mp. 170~171℃.(15) 2-trityloxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (anti isomer), mp. 170-171 ° C.
IR(Nujol) : 3300, 3150, 1680, 1635, 1520cm-1 IR (Nujol): 3300, 3150, 1680, 1635, 1520cm -1
NMR(d6-DMSO, δ) : 7.33(15H, s), 8.13(2H, s)NMR (d 6 -DMSO, δ): 7.33 (15H, s), 8.13 (2H, s)
(16) 2-(2-시클로펜텐-1-일) 옥시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 150℃ (분해).(16) 2- (2-cyclopenten-1-yl) oxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 150 ° C. (decomposition).
IR(Nujol) : 3300, 3150, 1710, 1620, 1520cm-1 IR (Nujol): 3300, 3150, 1710, 1620, 1520cm -1
NMR(d6-DMSO, δ) : 1.80-2.50(4H, m), 5.30-5.50(1H, m), 5.83-6.30(2H, m), 8.20(2H, s)NMR (d 6 -DMSO, δ): 1.80-2.50 (4H, m), 5.30-5.50 (1H, m), 5.83-6.30 (2H, m), 8.20 (2H, s)
(17) 2-(1-카르복시-3-하이드록시프로폭시이미노)-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 186~188℃ (분해).(17) 2- (1-carboxy-3-hydroxypropoxyimino) -2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 186-188 ° C (decomposition).
IR(Nujol) : 3400, 3250, 3100, 1710, 1620, 1540cm-1 IR (Nujol): 3400, 3250, 3100, 1710, 1620, 1540cm -1
NMR(DMSO-d6, δ) : 1.73-2.10(2H, m), 3.50(2H, t, J=6Hz), 4.73(1H, t, J=6Hz), 8.13(2H, s)NMR (DMSO-d 6 , δ): 1.73-2.10 (2H, m), 3.50 (2H, t, J = 6 Hz), 4.73 (1H, t, J = 6 Hz), 8.13 (2H, s)
(18) 2-에톡시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일)-아세트산 (syn 이성체), mp. 180~182℃ (분해).(18) 2-ethoxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) -acetic acid (syn isomer), mp. 180-182 ° C. (decomposition).
IR(Nujol) : 3450, 3250, 3100, 1715, 1610, 1530cm-1 IR (Nujol): 3450, 3250, 3100, 1715, 1610, 1530cm -1
NMR(d6-DMSO, δ) : 3.90(3H, s), 8.10(3H, broad s)NMR (d 6 -DMSO, δ): 3.90 (3H, s), 8.10 (3H, broad s)
(19) 2-프로폭시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 100~103℃ (분해).(19) 2-propoxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 100-103 ° C (decomposition).
IR(Nujol) : 3620, 3520, 3350, 3120, 2600, 2500, 1720, 1620, 1550cm-1 IR (Nujol): 3620, 3520, 3350, 3120, 2600, 2500, 1720, 1620, 1550cm -1
NMR(d6-DMSO, δ) : 1.00(3H, t, J=6Hz), 1.3-2.0(2H, m), 4.13(2H, t, J=6Hz), 8.17(2H, broad, s)NMR (d 6 -DMSO, δ): 1.00 (3H, t, J = 6 Hz), 1.3-2.0 (2H, m), 4.13 (2H, t, J = 6 Hz), 8.17 (2H, broad, s)
(20) 2-이소프로폭시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 152~155℃ (분해).(20) 2-isopropoxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 152-155 degreeC (decomposition).
IR(Nujol) : 3450, 3300, 3200, 1730, 1620, 1530cm-1 IR (Nujol): 3450, 3300, 3200, 1730, 1620, 1530cm -1
NMR(d6-DMSO, δ) : 1.22(6H, d, J=6Hz), 4.1-4.6(1H, m), 8.20(2H, broad s)NMR (d 6 -DMSO, δ): 1.22 (6H, d, J = 6 Hz), 4.1-4.6 (1H, m), 8.20 (2H, broad s)
(21) 2-(티오란-1,1-디옥사이드 3-일옥시이미노)-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 200~205℃ (분해).(21) 2- (thioran-1,1-dioxide 3-yloxyimino) -2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 200-205 ° C. (decomposition).
IR(Nujol) : 3300, 1720, 1620, 1530cm-1 IR (Nujol): 3300, 1720, 1620, 1530cm -1
NMR(d6-DMSO, δ) : 2.20-2.50(2H, m), 3.00-3.50(4H, m), 5.00-5.27(1H, m), 8.20(2H, s)NMR (d 6 -DMSO, δ): 2.20-2.50 (2H, m), 3.00-3.50 (4H, m), 5.00-5.27 (1H, m), 8.20 (2H, s)
(22) 2-(4-클로로펜옥시이미노)-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 150~155℃ (분해).(22) 2- (4-chlorophenoxyimino) -2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 150-155 ° C. (decomposition).
IR(Nujol) : 3300, 3200, 1710, 1640, 1580, 1530cm-1 IR (Nujol): 3300, 3200, 1710, 1640, 1580, 1530cm -1
NMR(DMSO-d6, δ) : 7.37(2H, d, J=9Hz), 7.67(2H, d, J=9Hz), 8.50(2H, broad s)NMR (DMSO-d 6 , δ): 7.37 (2H, d, J = 9 Hz), 7.67 (2H, d, J = 9 Hz), 8.50 (2H, broad s)
(23) 2-(4-플루오로펜옥시이미노)-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 140~145℃ (분해).(23) 2- (4-fluorophenoxyimino) -2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 140-145 ° C. (decomposition).
IR(Nujol) : 3450, 3300, 3200, 1730, 1630, 1530, 1500cm-1 IR (Nujol): 3450, 3300, 3200, 1730, 1630, 1530, 1500cm -1
NMR(DMSO-d6, δ) : 7.17(2H, s), 7.27(2H, s), 8.27(2H, s)NMR (DMSO-d 6 , δ): 7.17 (2H, s), 7.27 (2H, s), 8.27 (2H, s)
(24) 2-(1-페닐에폭시이미노)-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 103~107℃ (분해).(24) 2- (1-phenylepoxyimino) -2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 103-107 ° C. (decomposition).
IR(Nujol) : 3250, 3150, 1710, 1610, 1520cm-1 IR (Nujol): 3250, 3150, 1710, 1610, 1520cm -1
NMR(d6-DMSO, δ) : 1.57(3H, d, J=6Hz), 5.42(1H, q, J=6Hz), 7.40(5H, m), 8.20(2H, m)NMR (d 6 -DMSO, δ): 1.57 (3H, d, J = 6 Hz), 5.42 (1H, q, J = 6 Hz), 7.40 (5H, m), 8.20 (2H, m)
(25) 2-(2-메톡시-5-니트로펜옥시이미노)-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 125~128℃ (분해).(25) 2- (2-methoxy-5-nitropenoxyimino) -2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 125-128 ° C. (decomposition).
IR(Nujol) : 3400, 3280, 1740, 1720, 1690, 1630, 1590, 1510, 1340, 1275, 970, 720cm-1 IR (Nujol): 3400, 3280, 1740, 1720, 1690, 1630, 1590, 1510, 1340, 1275, 970, 720cm -1
NMR(DMSO-d6, δ) : 3.93(3H, s), 7.27(1H, d, J=8Hz), 8.01(1H, d, J=8Hz), 8.07(1H, s), 8.30(2H, broad s)NMR (DMSO-d 6 , δ): 3.93 (3H, s), 7.27 (1H, d, J = 8 Hz), 8.01 (1H, d, J = 8 Hz), 8.07 (1H, s), 8.30 (2H, broad s)
(26) 2-(3,4-디클로로펜옥시이미노)-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 177~178℃.(26) 2- (3,4-dichlorophenoxyimino) -2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 177-178 degreeC.
IR(Nujol) : 3300, 1710, 1625, 1585, 1530, 1300, 1210, 1120, 980cm-1 IR (Nujol): 3300, 1710, 1625, 1585, 1530, 1300, 1210, 1120, 980cm -1
NMR(DMSO-d6, δ) : 6.83-7.73(3H, m), 8.38(2H, broad s)NMR (DMSO-d 6 , δ): 6.83-7.73 (3H, m), 8.38 (2H, broad s)
(27) 2-(3-트리플루오로메틸펜옥시이미노)-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 167~168℃ (분해).(27) 2- (3-trifluoromethylphenoxyimino) -2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 167-168 ° C. (decomposition).
IR(Nujol) : 3250, 1645, 1620, 1590, 1450, 1320, 1170, 1140, 1010, 995, 845, 730cm-1 IR (Nujol): 3250, 1645, 1620, 1590, 1450, 1320, 1170, 1140, 1010, 995, 845, 730 cm -1
NMR(DMSO-d6, δ) : 7.63(4H, m), 8.44(2H, broad s)NMR (DMSO-d 6 , δ): 7.63 (4H, m), 8.44 (2H, broad s)
(28) 2-(3-카르복시펜옥시이미노)-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 186~188℃ (분해).(28) 2- (3-carboxyphenoxyimino) -2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 186-188 ° C (decomposition).
IR(Nujol) : 3420, 3150, 1735, 1690, 1620, 1580, 1265, 1200, 1000, 980, 760cm-1 IR (Nujol): 3420, 3150, 1735, 1690, 1620, 1580, 1265, 1200, 1000, 980, 760cm -1
NMR(DMSO-d6, δ) : 7.3-8.0(4H, m), 8.30(2H, broad s)NMR (DMSO-d 6 , δ): 7.3-8.0 (4H, m), 8.30 (2H, broad s)
(29) 2-(4-플루오로벤질옥시이미노)-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체),(29) 2- (4-fluorobenzyloxyimino) -2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer),
NMR(DMSO-d6, δ) : 8.10(2H, b, s), 7.63-6.98(4H, m), 5.20(2H, s)NMR (DMSO-d 6 , δ): 8.10 (2H, b, s), 7.63-6.98 (4H, m), 5.20 (2H, s)
(30) 2-헥실옥시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체), mp. 158~161℃.(30) 2-hexyloxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid (syn isomer), mp. 158-161 degreeC.
NMR(DMSO-d6, δ) : 0.67-2.00(11H, m), 4.20-4.38(2H, m)NMR (DMSO-d 6 , δ): 0.67-2.00 (11H, m), 4.20-4.38 (2H, m)
[실시예 12]Example 12
메탄올(935ml) 중의 나트륨 2-카르복시메톡시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세테이트 (syn 이성체) (50.0g)의 용액에 교반하에 농염산 (50ml)를 첨가하고, 실온에서 7시간 동안 유지시켰다.Conc. Hydrochloric acid under stirring to a solution of sodium 2-carboxymethoxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetate (syn isomer) (50.0 g) in methanol (935 ml) (50 ml) was added and kept at room temperature for 7 hours.
반응혼합물에 중탄산나트륨 (23.6g)과 물(100ml)를 첨가한 후, 혼합물을 증발시켜서 메탄올을 제거하였다. 수성잔사는 에틸아세테이트로 추출하였다.Sodium bicarbonate (23.6 g) and water (100 ml) were added to the reaction mixture, and the mixture was evaporated to remove methanol. The aqueous residue was extracted with ethyl acetate.
추출물은 마그네슘 설페이트로 건조시킨 후, 증발 건조시켰다. 잔사를 메탄올로 연화시켜서 여과한 후, 이소프로필 알코올로 세정하여 건조시켜서 2-메톡시카르보닐메톡시이미노-2-(5-아미노-1,2,4-티아디아졸-3-일) 아세트산 (syn 이성체) (15.5g)을 얻었다.The extract was dried over magnesium sulfate and then evaporated to dryness. The residue was triturated with methanol, filtered, washed with isopropyl alcohol and dried to give 2-methoxycarbonylmethoxyimino-2- (5-amino-1,2,4-thiadiazol-3-yl) acetic acid. (syn isomer) (15.5 g) was obtained.
m.p. 179°- 181℃ (분해)m.p. 179 ° -181 ° C (decomposition)
IR(Nujol-) : 3400, 3300, 3200, 2800-2200, 1750, 1710, 1615, 1520cm-1 IR (Nujol-): 3400, 3300, 3200, 2800-2200, 1750, 1710, 1615, 1520 cm -1
NMR(DMSO-d6, δ) : 3.63(3H, s), 4.77(2H, s), 8.10(2H, s)NMR (DMSO-d 6 , δ): 3.63 (3H, s), 4.77 (2H, s), 8.10 (2H, s)
Claims (2)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8107134 | 1981-03-06 | ||
GB8107134 | 1981-03-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR830009067A KR830009067A (en) | 1983-12-17 |
KR880001762B1 true KR880001762B1 (en) | 1988-09-12 |
Family
ID=10520204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR8200972A KR880001762B1 (en) | 1981-03-06 | 1982-03-06 | Processes for preparing 2-substituted hydroxyimino-2-(5-amino-1,2,4-thiadiazol-3-yl)acetic or tis salt |
Country Status (3)
Country | Link |
---|---|
JP (2) | JPS57158769A (en) |
KR (1) | KR880001762B1 (en) |
GB (1) | GB2094794B (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0717622B2 (en) * | 1986-06-05 | 1995-03-01 | エーザイ株式会社 | Thiadiazolylacetamide derivative |
JPH0625187B2 (en) * | 1986-12-10 | 1994-04-06 | エーザイ株式会社 | Thiadiazole derivative |
JPH0699449B2 (en) * | 1988-03-16 | 1994-12-07 | エーザイ株式会社 | Synthetic intermediate of cephem derivative |
IE902556A1 (en) * | 1989-07-19 | 1991-02-27 | Fujisawa Pharmaceutical Co | Processes for preparing 2-substituted¹hydroxyimino-2-(5-amino-1,2,4-thiadiazol-3-yl) acetic acid¹or its salts |
CN101962371B (en) * | 2010-10-13 | 2013-07-24 | 浙江工业大学 | Method for preparing ceftobiprole side chain acid and key intermediate thereof |
CN102093266B (en) * | 2011-01-21 | 2013-07-24 | 蚌埠丰原医药科技发展有限公司 | Method for preparing O-tosyl-2-carbamoyl-2-methoxyl-imido-acetamido-oxime |
JP6327754B2 (en) * | 2013-06-21 | 2018-05-23 | クミアイ化学工業株式会社 | Process for producing 2-amino-2-hydroxyimino-N-alkoxyacetimidoylcyanide and its intermediate |
CN103804321B (en) * | 2014-02-18 | 2016-03-02 | 陕西思尔生物科技有限公司 | (Z) preparation method of-5-amino-α-(ethoxy imino)-1,2,4-thiadiazoles-3-acetic acid |
CN104177408B (en) * | 2014-09-12 | 2016-09-07 | 衡水衡林生物科技有限公司 | (Z) preparation method of-2-(5-dichlor-phosphoryl amino-1,2,4-thiadiazoles-3-base)-2-ethoxyimino chloroacetic chloride |
CN105330612B (en) * | 2015-11-04 | 2018-04-03 | 上海泰坦科技股份有限公司 | The synthesis technique of 2 (base of 5 amino, 1,2,4 thiadiazoles 3) 2 methoxyimino acetic acid |
WO2018053587A1 (en) * | 2016-09-21 | 2018-03-29 | Vectus Biosystems Limited | Compositions for the treatment of hypertension and/or fibrosis |
CN110713443B (en) * | 2018-07-13 | 2022-01-28 | 沈阳中化农药化工研发有限公司 | Process for preparing malononitrile oxime ether compounds and intermediate compounds |
CN109096224A (en) * | 2018-09-27 | 2018-12-28 | 陕西思尔生物科技有限公司 | A kind of synthetic method of Ceftobiprole side-chain acid |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS576425B2 (en) * | 1972-06-19 | 1982-02-04 | ||
JPS4924963A (en) * | 1972-06-27 | 1974-03-05 | ||
JPS5537556B2 (en) * | 1973-12-27 | 1980-09-29 | ||
HU183006B (en) * | 1978-12-29 | 1984-04-28 | Fujisawa Pharmaceutical Co | Process for producing 7-substituted-3-cepheme- and cephame-4-carboxylic acid derivatives |
-
1982
- 1982-03-01 GB GB8205933A patent/GB2094794B/en not_active Expired
- 1982-03-05 JP JP57035693A patent/JPS57158769A/en active Granted
- 1982-03-06 KR KR8200972A patent/KR880001762B1/en active
-
1991
- 1991-10-30 JP JP3349290A patent/JPH0629272B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPS57158769A (en) | 1982-09-30 |
JPH0629272B2 (en) | 1994-04-20 |
GB2094794A (en) | 1982-09-22 |
KR830009067A (en) | 1983-12-17 |
JPH05186447A (en) | 1993-07-27 |
GB2094794B (en) | 1985-02-20 |
JPH0476990B2 (en) | 1992-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR880001762B1 (en) | Processes for preparing 2-substituted hydroxyimino-2-(5-amino-1,2,4-thiadiazol-3-yl)acetic or tis salt | |
RU2378261C2 (en) | Method of preparing salt compound (4,5-dihydroisoxazol-3-yl)thiocarboxamidine | |
EP0286145A2 (en) | 3-Heterocyclylthiomethyl cephalosporins | |
US4500716A (en) | Intermediate products for the preparation of Z-cephalosporins | |
JPH0448796B2 (en) | ||
FI84268B (en) | 7 -AMINO-3-PROPENYLCEFALOSPORANSYRA OCH DESS ESTRAR OCH ETT FOERFARANDE FOER FRAMSTAELLNING AV DESSA. | |
KR910000238B1 (en) | Process for preparing thiazole derivatives | |
US20140350240A1 (en) | Process for preparing ceftaroline salts or hydrates thereof | |
US4324741A (en) | Perfluoroalkyl compounds and process for preparing the same | |
KR100517007B1 (en) | Process for the preparation of nicotinic acids | |
CA1104561A (en) | 7-[(sulfomethyl)phenyl] acetamidocephalosporin derivatives | |
EP1603876B1 (en) | Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto esters | |
US4888429A (en) | Process for producing allyl aminothiazole acetate intermediates | |
ES2238029T3 (en) | PROCEDURE FOR THE PREPARATION OF DERIVATIVES OF TIAZOL. | |
EP0246603A2 (en) | 4-Halogeno-2-Oxyimino-3-Oxobutyric acids | |
KR100899325B1 (en) | Process for producing 1-oxacephalosporin-7?-methoxy-3-chloromethyl derivative | |
EP0117872B1 (en) | Process for preparing cephalosporin compounds | |
EP0135683B1 (en) | Method for production of cephalosporin compounds | |
CA2590494A1 (en) | Method for the production of oxazoles by condensing aromatic aldehydes with a-ketoximes to n-oxides and then reacting the same with activated acid derivatives | |
DK141909B (en) | Process for Preparation of 7-Aminocephalosporanoic Acids. | |
KR880001990B1 (en) | Process for preparing penicillin and cephalosporin intermediate compounds | |
JPH0345067B2 (en) | ||
KR0129567B1 (en) | The process for preparation of cephalosporins | |
KR830002742B1 (en) | Process for preparing thiadiazole compound | |
KR20230135108A (en) | Method for producing 2-[2-(2-chlorothiazol-5-yl)-2-oxo-ethyl]sulfanyl-6-hydroxy-3-methyl-5-phenyl-pyrimidin-4-one |